This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
CNCE 주식 개요
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
Concert Pharmaceuticals, Inc. 경쟁사
가격 내역 및 성능
| 과거 주가 | |
|---|---|
| 현재 주가 | US$8.37 |
| 52주 최고치 | US$8.55 |
| 52주 최저치 | US$2.66 |
| 베타 | 0.52 |
| 11개월 변경 | 0% |
| 3개월 변경 사항 | 92.86% |
| 1년 변경 사항 | 203.26% |
| 33년 변화 | -9.22% |
| 5년 변화 | -64.31% |
| IPO 이후 변화 | -40.97% |
최근 뉴스 및 업데이트
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03주주 수익률
| CNCE | US Biotechs | US 마켓 | |
|---|---|---|---|
| 7D | -0.1% | -1.6% | -0.06% |
| 1Y | 203.3% | 10.4% | 20.5% |
수익률 대 산업: CNCE exceeded the US Biotechs industry which returned 8.9% over the past year.
수익률 대 시장: CNCE exceeded the US Market which returned -5.5% over the past year.
가격 변동성
| CNCE volatility | |
|---|---|
| CNCE Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: CNCE's share price has been volatile over the past 3 months.
시간에 따른 변동성: CNCE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
회사 소개
| 설립 | 직원 | CEO | 웹사이트 |
|---|---|---|---|
| 2006 | 64 | Roger Tung | www.concertpharma.com |
Concert Pharmaceuticals, Inc. 기본 사항 요약
| CNCE 기본 통계 | |
|---|---|
| 시가총액 | US$520.71m |
| 수익(TTM) | -US$126.68m |
| 수익(TTM) | US$32.04m |
16.3x
P/S 비율-4.1x
P/E 비율CNCE 주가가 과대평가되어 있나요?
공정 가치 및 가치 분석 보기수익 및 수익
| CNCE 손익 계산서(TTM) | |
|---|---|
| 수익 | US$32.04m |
| 수익 비용 | US$102.70m |
| 총 이익 | -US$70.66m |
| 기타 비용 | US$56.02m |
| 수익 | -US$126.68m |
최근 보고된 수익
Sep 30, 2022
다음 수익 날짜
n/a
| 주당 순이익(EPS) | -2.04 |
| 총 마진 | -220.53% |
| 순이익 마진 | -395.36% |
| 부채/자본 비율 | 0% |
CNCE 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기